Trial Profile

Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HuMax IL8 (Primary) ; Nivolumab (Primary) ; Degarelix
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms MAGIC-8

Most Recent Events

29 Apr 2025 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
21 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Jan 2025.
21 Dec 2023 Planned primary completion date changed from 1 Oct 2023 to 1 May 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com